Milton H. Werner

Milton H. Werner is a declared insider of Inhibikase Therapeutics, Inc. (chief executive), with filings sourced from SEC (Form 4). We count 12 filings; the first trade dates from 14 May 2021 and the latest from 16 August 2022.

No open-market sale appears; the market trades are 8 purchases worth €55k. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Besides market trades, the filings include 1 share grant and 3 option exercises. 2022 to date brings 3 purchases and no sales.

Half of the purchases are above €4,240 and half below. On 2 out of 8 purchases, another insider of the same company was buying within the same 30 days. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time.

The record was last updated on 16 August 2022 with an open-market purchase (€3,933) in Inhibikase Therapeutics, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. For comparison, the SEC allows two business days to file a Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.